HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

HCT 3012

a nitric-oxide releasing derivative of naproxen

Also Known As:

HCT-3012

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        Naphthaleneacetic Acids
        Naproxen: 2141
        HCT 3012: 4
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - Naphthaleneacetic Acids
      - Naproxen: 2141
        HCT 3012: 4

Experts

1.	McKnight, W: 2 articles (08/2000 - 02/2000)
2.	Muscará, M N: 2 articles (08/2000 - 02/2000)
3.	Wallace, J L: 2 articles (08/2000 - 02/2000)
4.	Cirino, Giuseppe: 1 article (12/2004)
5.	Di Lorenzo, Annarita: 1 article (12/2004)
6.	Farneti, Silvana: 1 article (12/2004)
7.	Fiorucci, Stefano: 1 article (12/2004)
8.	Morelli, Antonio: 1 article (12/2004)
9.	Renga, Barbara: 1 article (12/2004)
10.	Berti, Ferruccio: 1 article (08/2004)

Related Diseases

1.	Ischemia 08/01/2004 - "In this study, the pharmacological activity of HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphtaleneacetic acid 4-(nitrooxy)butyl ester], a nitric oxide (NO)-releasing derivative of naproxen, was compared with that of naproxen in a model of acute ischemia (40 min) and reperfusion (20 min) of the rabbit heart. "
2.	Hypertension (High Blood Pressure) 08/01/2004 - "The safer gastrointestinal profile of HCT-3012 and its ability to control experimental hypertension, suggest that this compound may have therapeutical potential in cardiovascular disease, namely in the prevention of myocardial ischemic events, and may represent a better alternative to conventional nonsteroidal anti-inflammatory drugs." 08/01/2000 - "Hypertension was induced by partially occluding one renal artery (the "2K,1C" model), and 2 wk later the rats started receiving naproxen, the nitric oxide-releasing derivative HCT-3012, or vehicle each day for 2 wk. Naproxen significantly exacerbated the hypertension. "
3.	Wounds and Injuries (Trauma) 02/01/2000 - "These results demonstrate that HCT-3012 can significantly enhance collagen deposition at a wound site, despite inhibiting prostaglandin synthesis to the same extent as the parent drug. " 02/01/2000 - "Naproxen and HCT-3012 suppressed prostaglandin (PG) E(2) levels at the wound site and whole blood thromboxane synthesis to similar degrees. "
4.	Inflammation (Inflammations) 12/01/2004 - "In contrast, coadministration of HCT-3012 (15 mg/kg/day) significantly attenuated arthritis development, because HCT-3012 was equally or more effective than naproxen and celecoxib in attenuating local and systemic inflammation (P >0.001 versus arthritis) without exacerbating gastric mucosal injury caused by ASA. "
5.	Cardiovascular Diseases (Cardiovascular Disease) 08/01/2004 - "The safer gastrointestinal profile of HCT-3012 and its ability to control experimental hypertension, suggest that this compound may have therapeutical potential in cardiovascular disease, namely in the prevention of myocardial ischemic events, and may represent a better alternative to conventional nonsteroidal anti-inflammatory drugs."

Related Drugs and Biologics

1.	Naproxen (Naprosyn)
2.	Nitric Oxide (Nitrogen Monoxide)
3.	Esters
4.	Acids
5.	S 6 (S-6)
6.	Thromboxanes
7.	Prostaglandins
8.	Collagen
9.	Celecoxib (Celebrex)